University College London Hospitals NHS Foundation Trust

Genetic Prion Disease and How Genetics Might Help Us Understand Sporadic CJD

Ρ

UCL

MRC

Prion Unit

Professor Simon Mead National Prion Clinic, University College London (UCL) Hospitals NHS Foundation Trust MRC Prion Unit at UCL

Aims

- Describe prions, DNA, prion diseases, and genetic forms of the diseases
- Genes that alter the risk of getting sporadic CJD
- What does this mean for families?
- Inherited prion diseases, special opportunities
- How do these discoveries help us understand the diseases?
- Update on PRN100 treatment in London

Some of the first conversations we hear concern genetics



- How we have our "grandmother's nose" or "father's eyes"
- Identical twins striking example of effects of genetics
- Similarities beyond the superficial
- Genes determine to some extend which diseases we get
- Genes are variable between people in a population, some changes in the DNA code are common, some are very rare
- Disease risks are a mixture of genetic, environmental and bad luck influences, the relative contributions vary between diseases

Three main causes of prion disease

Sporadic Creutzfeldt-MAIN EXPLANATION **Bad luck** Jakob disease Inherited prion Genetic disease (mutation in the prion protein gene) Acquired prion **Exposure to prions** in the diet diseases: Variant CJD medical procedures latrogenic CJD

Sporadic Creutzfeldt-Jakob disease

- Typically a rapidly progressive dementia with neurological features like jerky muscle movements and loss of balance
- Most patients will die with six months of onset
- Occurs seemingly at random in populations
- Risk over a lifetime ~1:5000 (cumulative of 1-2 per million per year)
- Doesn't run in families, no known exposures (rare concurrences in families are to be expected)

Sporadic Creutzfeldt-Jakob disease

- BAD LUCK
- Spontaneous change in folding of prion protein or mutation of a single DNA molecule to make a mutant prion protein
- Reason to research genetics in CJD is to find molecular processes that influence/modify risk
- This might mean going from a lifetime risk of 1:5000 to 1:4000
- If you want to tackle a problem best to try and get a good understanding

Inherited prion disease

- Very varied types of brain diseases
- Can look just like CJD clinically
- Can present with fragmented sleep, problems with blood pressure, temperature, sweating (fatal familial insomnia)
- Can cause balance problems first, then later difficulty thinking (Gerstmann-Straussler-Scheinker syndrome) over 4-5 years
- Some cause very slowly progressive problems with thinking (prion protein gene insertions)
- Rarely causes problems with sensation and diarrhoea over many decades (truncation mutations)


Inherited prion disease

- All are caused by mutation (error in DNA code) in the gene that makes the prion protein
- We offer this test for all patients with apparently sporadic CJD
- This variation explains most of the risk of the inherited disease for a persons lifetime
- Some additional genetic changes may influence when the disease starts or the main symptoms (eg. codon 129 in prion protein gene)
- We research genetics in inherited prion diseases to be confident which mutations cause which diseases at what age in order to better counsel people and help make choices
 - About reproduction
 - About having a test to see if a mutation has been inherited

Inherited prion disease

- People may learn they are at-risk of inherited prion disease after a diagnosis in a blood relative
- Special opportunities eg.
- To decide whether to have a test to see if you have inherited the mutation
- To decide whether or not to have children that might inherit the mutation
- Potentially to join studies or trials that aim to predict or prevent the disease

Cells and DNA







Simplified cell, containing different structures


DNA, different colours reflecting the "code"

The code is translated to make proteins




Normal human prion protein and the prion mechanism






Normal prion protein, one of >100,000 different body proteins Abnormal prion protein, grows by binding and misfolding the normal form


PRNP—The gene that makes prion protein



Variants in *PRNP* influence risk of disease in different ways



Slopes of sCJD decline stratified by codon 129 genotype



Genotypes MM and VV confer increased risk

UK Cohort study ~940 enrolled to date

Age and gender not strong factors affecting progression


Codon 129 is a powerful factor. It determines prion strain, and rates of progression. Fundamental to understanding CJD

Summary so far

- Covered the causes and symptoms of prion diseases
- Molecular mechanisms including powerful effects of genetic variation at prion protein gene
- Now some of the research to find new genes for CJD


Genome wide association study

Patients diagnosed with at least probable CJD




Healthy population control individuals


Collaborative sCJD sample collection: Discovery




Collaborative sCJD sample collection: Replication



Principle components analysis



Manhattan Plot



Chromosome


Overall Results

CHR	SNP	Nearest Gene	% in CJD	% in population	Combined P	Combined OR
1	Rs3747957 (A)	STX6	45	41	1.23 x 10 ⁻¹⁰	1.14
20	Rs1799990 (A)	PRNP	34	29	9.61 x 10 ⁻¹⁷	1.15
22	Rs2267161 (C)	GAL3ST1	71	68	1.97 x 10 ⁻¹⁰	1.11

Summary so far


- Confident in three genetic effects that alter the risk of getting CJD
- What does this mean?
- How do the genetic effects work?

The genetic variant that confer risk of CJD makes more *STX6* in the brain




Syntaxin 6 expression

sCJD; cerebellum; Atlas Antibodies HPA038558 rabbit polyclonal IgG



Images prepared by Prof Sebastian Brandner, Zane Jaunmuktane, Jackie Linehan

Syntaxin-6 is a protein inside cells involved in the decision for vesicles to fuse with membranes



STX6 is a known risk factor for Progressive Supranuclear Palsy, an uncommon neurodegenerative disease that can be mistaken for Parkinson's disease


Genetic effects seem to work the same way (same variants confer risk)

Shared mechanisms in related disorders

What about *GAL3ST1*?

- Encodes galactocerebroside sulfotransferase
- Genetic variant encodes V29M change
- May affect metabolism of brain lipids
- Why this is important for CJD is the subject of further research

What about *GAL3ST1*?



Conclusions (genetics)

- Through kind contribution of DNA samples from around the world (mostly European ancestries populations) we have discovered new genes that increase the risk of CJD
 - STX6 and GAL3ST1
- These are small but confident changes, with no implications for families, no change in risk for relatives of patients with sporadic CJD
- It helps us understand sporadic CJD better, at present main target for treatments and diagnosis is prion protein
- Going on to look at genetic determinants of how fast the disease progresses, and age it starts



PRN100: Progress with special needs treatment

Health

Pioneering CJD treatment to be used on British patient

Home

News

More

By Alex Therrien Health reporter, BBC News

BBC O

NEWS

() 9 October 2018

🔗 🈏

Q



Doctors have been given permission to give a British man with CJD a pioneering treatment, in a world first.

- First patient commenced PRN100 October 2018 following legal hearing at Court of Protection
- Treatment judged to be in patients best interest and lawful
- Five further patients treated with available drug stock: two were judged to have mental capacity able to consent
- No acute drug reactions and no evidence side effects after several months treatment at highest doses
- No need to progress to ICV (IV CSF levels encouraging)
- Cannot be clear whether clinical response given highly variable clinical course of CJD and small numbers
- All patients have now died
- See UCLH website for Q&A and updates: http://www.uclh.nhs.uk/News/Pages/Prion CJD.aspx



Kirsty Joanna McNiven Field Akin Nihat Selam Tesfamichael

Veronica O'Donnell

ica Regina inell Appenteng

Peter Rudge

Prion immunotherapeutics

Azy Khalili-Shirazi, Simon Mead, Nicola Muirhead, Caroline Potter, Stephanie Canning, Jacqueline McDonald, Peter-Christian Klöhn, Michael Farmer, Jacqueline M Linehan, Catherine O'Malley, Mar Fernandez de Marco, William Taylor, Mark Farrow, Sebastian Brandner

Funders: MRC; UCLH NIHR BRC; Jon Moulton Charitable Foundation; CureCJD Campaign



Prion Unit

MRC





www.prion.ucl.ac.uk www.nationalprionclinic.org

Acknowledgements

MRC Prion Unit at UCL

Emma Jones (PhD student) Athanasios Dimitriadis (PhD student) Liam Quinn (PhD student) James Uphill Holger Hummerich Ron Druyeh **Tracy Campbell** Penny Norsworthy Emmanuelle Vire Will Taylor Helen Speedy Jerome Whitfield Jackie Linehan Zane Jaunmuktane Sebastian Brandner John Collinge

National Prion

Clinic Staff

PNGIMR Michael Alpers

Germany

Inga Zerr Saima Zafar

France

Stephane Haik Jean-Louis Laplanche Jean-Philippe Brandel

USA Pierluigi Gambetti Brian Appleby Michael Geschwind

Piero Parchi Fabrizio Tagliavini Maurizio Pocchiari Anna Poleggi Anna Ladogana

UCL Genetics Vincent Plagnol Doug Speed Switzerland Herbert Budka Adriano Aguzzi

Austria Gabor Kovacs

Scotland Richard Knight

Netherlands SJ van Der Lee Cornelia Van Duijn

Australia Steve Collins

Spain

Miguel Calero Pascual Sanchez Juan

Poland Pawel Liberski